GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications
16.3.2026 13:00:00 CET | Business Wire | Press Release
GCE®, a global market leader for gas control equipment, has launched gascontrol.com, a new website designed to better serve customers across its GCE Specialty, GCE Medical, and GCE Industrial product portfolios. The new site provides a streamlined, market-focused experience that makes it easier for users to explore GCE’s gas control solutions and identify the right products. A new Documentation Search Tool assists customers in easily finding documents such as instructions for use (IFUs), appendices, and certifications through an intuitive search interface.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316410525/en/
GCE’s new website, gascontrol.com, provides a streamlined, market-focused experience across the GCE Specialty, GCE Medical, and GCE Industrial product portfolios.
“The redesigned website reflects GCE’s role as a comprehensive, trusted supplier of gas control technologies that elevate industries and improve lives,” says Piyush Sheth, Vice President and General Manager, GCE. “With improved navigation, content organized by application and industry, and a list of global contacts, the site is intended to support engineers, clinicians, system designers, distributors, and procurement teams throughout the decision-making process.”
Three Product Groups
Backed by ESAB Corporation (NYSE: ESAB), GCE has grown its global footprint through the merging of leading gas-equipment providers, expanding its reach across the Americas, Asia, and Europe. Its products undergo rigorous testing and certifications to meet international quality and safety standards. GCE is organized into three product divisions:
GCE Speciality (gce-speciality.com) — incorporating the druva®, GASARC® and Victor®, brands — caters to high-purity market sectors such as pharmaceutical, semiconductor and automotive manufacturing, analytical laboratories, food and beverage, refrigeration, and industrial applications. GCE engineers regulators, manifolds, and other specialized products to maintain gas purity and deliver consistent, repeatable performance in environments where even minor contamination or pressure variation can impact results. GCE’s FloCloud digital solution enables users to monitor gas levels, detect gas leaks and confirm system integrity, monitor consumption, identify over-consumption, ensure gas flow and pressure are within limits for consistent quality, and allocate costs.
GCE Medical (gce-medical.com) — incorporating GCE Healthcare, Therapy Equipment, Ohio Medical, DeltaP and Aktiv Technologies brands — serves pre-hospital, hospital, emergency, and home care medical settings. Products include medical source gas equipment, medical high-pressure regulators, gas manifolds and pipeline systems, oxygen concentrators, ambulance panels, emergency equipment, and other products that ensure the safe and reliable delivery of life-supporting gases from source to patient.
GCE Industrial (gce-industrial.com) — incorporating the Kayser brand — has its origins in oxy fuel welding and cutting and has expanded into segments that use regulators, valves, central gas supply systems, cutting and welding torches and equipment, welding consumables, and safety gear. In industrial applications, the FloCloud Industry 4.0 gas monitoring solution reduces the costs and chance of error that comes from manually checking gas levels, reduces the cost of waste associated with parameters being out of specification, and reduces the chance of interrupted flow, and helps detect leaks.
About GCE
GCE Group, part of ESAB Corporation (NYSE: ESAB), is a leading global manufacturer of gas control equipment. Driven by innovation across our brands, including Ohio® Medical and Therapy Equipment, we strive to deliver the highest quality gas control products and services. Our portfolio offers market compliant, industry leading solutions for the medical, industrial and specialty gas industries. With international manufacturing, sales, and supply, we ensure customers can always access the world’s leading innovative gas control equipment. To learn more, visit https://www.gascontrol.com/en/about-us
PR-23132
View source version on businesswire.com: https://www.businesswire.com/news/home/20260316410525/en/
Contacts
ContactShaun Heys
Telephone+41 41 560 07 00
Cell+44 (0)7935 711 355
EmailShaun.heys@gcegroup.com
Websitewww.gcegroup.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.gcegroup.co
m&esheet=54448271&newsitemid=20260316410525&lan=en-US&anchor=www.gcegroup.com&in
dex=3&md5=c269aa14bf9688b837dc41340c16695f
ESAB Corporation Media Contact:
Tilea Coleman
Tel +1 (301) 323-9092
mediarelations@esab.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press Release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 16:25:00 CEST | Press Release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press Release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press Release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press Release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom